# **Special Issue**

## Viroids 2022

## Message from the Guest Editor

It has been fifty years since the first viroid was discovered in 1971. Through the efforts of the first and second generation of viroidologists, there has been great progress in the viroid research. Yet as time goes by, some of these veterans have passed away, and the rest would also gradually withdraw from the historical stage of viroid research. In this special moment, Viruses established a Special Issue called Viroid 2022, aiming to look back to the accomplishment of the half-century history of viroid research, and at the same time, raise the awareness of this new type subviral agent and related diseases, especially among the young biologists.

#### **Guest Editor**

Prof. Dr. Shifang Li

Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing, China

### Deadline for manuscript submissions

closed (31 December 2022)



# **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



## mdpi.com/si/108616

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





# Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

### **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

